Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Gaithersburg, USA
21 Firstfield Road
Suite 200
Gaithersburg, MD, 20878
USA

People

Board Director
director
Chairman
Board Observer

Funding

TOTAL $25M
FUNDING TOTAL $25M
Series A, 9/2010
New Enterprise Associates
$25M

Tags

Zyngenia

Founded in 2008, Zyngenia, Inc. is a privately held biotherapeutics company focused on the development of the next-generation of antibody-derived drugs. The company uses proprietary technology to enable the development of singular molecular entities that address two or more targets, by combining the activity of two or more biologic therapies into one protein (known as a Zybodyâ„¢). In addition, the technology will also be applied to drug targets that previously have not been reachable through the use of traditional, single specificity, monoclonal antibodies.

Recent Milestones

Videos

Screenshots

Zyngenia screenshot
Above: Home Page
Uploaded: 2/3/10

Sources

  1. New Enterprise Associates Extends Zyngenia Series A To $25M (fis.dowjones.com) [edit]
Edit This Page
Last Edited 3/11/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy